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Introduction
Enhancing lesions that arise on brain MR imaging at the
site of a previously treated neoplasm present a signifi-
cant clinical dilemma. Most of these neoplasms have
been subjected to radiation and/or chemotherapy and
many do not have specific imaging characteristics that
will enable the neuroradiologist to discriminate tumor
recurrence from the inflammatory or necrotic change
that can result from treatment with radiation and/or
chemotherapy. Both typically demonstrate contrast
enhancement. It is, therefore, often the clinical course, a
brain biopsy, or imaging over a lengthy follow-up
interval that enables the distinction of recurrent tumor
from a treatment-related lesion and not the specific
imaging itself [1]. A non-invasive tool that could differ-
entiate between these entities when a new enhancing
lesion is first identified would be invaluable. MR spec-
troscopy is well suited for this purpose, provided that
spectra of diagnostic quality can be obtained.
In the supratentorial compartment, MR spectroscopy
(MRS) has proven useful in the evaluation of many
central nervous system neoplasms, often enabling the
distinction of neoplasm from normal tissue or from
radiation necrosis [2]. MRS results have been shown to
correlate with histopathology from biopsy [3, 4] and
resection specimens [5]. MRS has been used to differ-
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Abstract Recurrent contrast-enhanc-
ing lesions arising within foci of
prior brain neoplasms treated with
chemotherapy and/or radiation
therapy pose a significant diagnostic
dilemma, as they may represent
recurrent or residual tumor,
treatment-related changes, or a
combination of both. Those lesions
specifically in the posterior fossa are
even more difficult to assess, given
the technical limitations of 2D CSI
in the infratentorial compartment.
We explored the feasibility of
2D-CSI MR spectroscopy in the
evaluation of recurrent contrast-
enhancing lesions in eight
consecutive patients who had
undergone treatment for posterior
fossa or brainstem tumors. Mean
Cho/Cr (choline/creatine) ratios
obtained by 2D-CSI in recurrent
tumor, treatment-related changes,
and normal white matter were 2.93,
1.62, and 0.97, respectively, mean
Cho/NAA (choline/N-Acetyl
aspartate) ratios were 4.34, 1.74, and
0.93, and mean NAA/Cr (N-acetyl
aspartate/creatine) ratios were 0.74,
0.92, and 1.26, respectively. In
conclusion, also in the posterior
fossa, MR spectroscopy is likely to
be useful as an adjunct to conven-
tional imaging characteristics in
distinguishing recurrent tumor from
treatment-related changes, irrespec-
tively of the MRS technique used. In
most cases spectra of diagnostic
quality can be obtained using
2D-CSI to include coverage of both
the lesion and its vicinity.
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shown correlates of radiation necrosis and tumor pro-
gression [6]. Also, specific spectroscopic changes that
occur after radiation-induced tumor necrosis have been
reported [7, 8]. MR spectroscopy has been used with
promising results in guiding CNS tumor biopsy and
surgical planning [9], and in preoperative grading
of gliomas with increased choline content correlating
directly with increased tumor grade [4, 10, 11]. The
clinical impact of spectroscopy on the assessment of
contrast-enhancing lesions that have indeterminate
imaging characteristics has also been reported [12, 13].
Although the utility of MRS with respect to neo-
plasm-related lesions has been demonstrated in the su-
pratentorial compartment [4, 10, 12–14], there are no
dedicated reports evaluating the role of MRS in lesions
within the infratentorial compartment. Tumors located
in the posterior fossa are often histologically unique and
are technically challenging with regard to management
and treatment. Performing MR spectroscopy in the
posterior fossa is difficult because of the close proximity
to the skull base, surrounding calvarium, and the rela-
tive amount of air- and fluid-filled spaces compared to
the brain parenchyma. As a result, characterization of
contrast-enhancing lesions in the posterior fossa with
MR spectroscopy is technically challenging [15] and has
often failed because of bulk magnetic susceptibility
artifacts and in-field inhomogeneity.
The feasibility of performing 2D CSI (two-dimen-
sional chemical shift imaging) MR spectroscopy in the
posterior fossa on normal brain, using multiple outer-
volume suppression slices (OVS) for lipid suppression,
has been shown [15]. However, in some subjects, exten-
sive artifact occurs and SVS (single voxel spectroscopy)
must then be used to generate diagnostic spectra. While
SVS generally yields greater signal to noise, it also re-
sults in the averaging of metabolite concentrations over
a wide region and decreases the sensitivity in detecting
focal metabolite differences that may be required to
distinguish tumor recurrence from tumor necrosis. Two-
dimensional-CSI MR spectroscopy enables multiple
regions in the posterior fossa to be interrogated during
the same acquisition. This enables a sampling of
multiple discrete regions, which may be necessary to
discern subtle differences between tumor recurrence and
necrosis or, perhaps more importantly, the identification
of discrete areas of both recurrent tumor and necrosis
in the same lesion. In addition, multiple regions of a
specific lesion can be explored in an attempt to find the
region with the least artifact. However, some lesions
may have such severe magnetic field inhomogeneity or
be sufficiently large and homogeneous that single-voxel
spectroscopy will result in spectra with a quality that is
superior to 2D CSI.
As a result, most authors have used SVS in the pos-
terior fossa almost exclusively. SVS has been used to
characterize more diffuse disease processes, such as
multisystem atrophy [16], spinocerebellar ataxia [17],
and alcoholism [18]. To our knowledge, the feasibility
and utility of 2D-CSI MR spectroscopy in the evalua-
tion of neoplasms in the posterior fossa and their
discrimination from treatment related changes have not
been demonstrated.
In this investigation we sought to demonstrate the
feasibility of performing 2D-CSI spectroscopy in the
evaluation of recurrent contrast-enhancing lesions in the
cerebellum and brainstem in eight patients with known
neoplasms in these regions who had undergone radiation
and/or chemotherapy.
Materials and methods
Eight patients, including four males and four females
(aged 4-61 years, mean 25 years) were evaluated. Their
demographic data and tumor histologic types are listed in
Table 1. Spectroscopy was performed on these eight
consecutive patients who were examined at the request of
the referring physician in an attempt to evaluate a recur-
rent contrast-enhancing lesion as potentially tumor
recurrence or tissue necrosis. The duration between the
completion of chemotherapy/radiation therapy and the
development of a new enhancing lesion on follow-up
MR imaging was 8–28 months. Exemption by our
Institutional Review Board (IRB) was obtained for this
Table 1 Patient demographics and tumor histologic types
Patient no. Sex Age Tumor type Treatment Follow-upduration Type of MRS
1 M 61 Brainstem glioma Radiation 8 months SVS
2 F 33 Brainstem glioma Radiation/chemotherapy 8 months 2D-CSI
3 F 41 Cerebellar
astrocytoma
Radiation/surgery 28 months 2D-CSI
4 M 4 Medullary glioma Surgery/chemotherapy 19 months 2D-CSI
5 M 17 Medullary glioma Radiation/chemotherapy 24 months 2D-CSI
6 F 16 Medulloblastoma Surgery/radiation/ chemotherapy 9 months 2D-CSI
7 M 12 Medulloblastoma Surgery/radiation/chemotherapy 12 months SVS
8 F 19 AML with CNS
involvement
Radiation/chemotherapy 11 months 2D-CSI
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study. Three patients had contrast-enhancing lesions in
the brainstem, and in four patients the lesion was in the
cerebellum or cerebral peduncles. One patient had lesions
in the cerebellum as well as in both cerebral hemispheres.
Examinations were performed on a 1.5 T scanner
(GE Medical Systems, Milwaukee, USA). A conven-
tional MRI examination that was performed in con-
junction with the MR spectroscopy included: pre- and
postcontrast-enhanced axial and sagittal T1-weighted,
axial T2-weighted sequence with fat saturation, axial
FLAIR and diffusion-weighted images, and postcon-
trast-enhanced T1-weighted images in the coronal pro-
jection. All MR spectroscopy examinations were
performed as the last series in the study and therefore
were always performed after the administration of gad-
olinium (gadopentate).
Seven patients underwent 2D CSI. The following
parameters were used for the 2D-CSI spectroscopy:
PRESS sequence, TE/TR 144/1000 ms, field of view
(FOV) 16 cm, matrix 16·16, slice thickness 10–20 mm,
acquisition 1 average, scan time 4:20 min. The VOI was
placed on non-angled contrast-enhanced axial T1-
weighted or on non-angled FLAIR images, depending
on which image best displayed the lesion. The VOI was
placed to include both the lesion and adjacent normal-
appearing cerebellum. Within the VOI, the signal
intensity in voxels placed both in the lesion and in
adjacent normal-appearing cerebellum was evaluated.
During voxel placement by the neuroradiologist,
attempts were always made to perform 2D CSI. How-
ever, in one patient (no. 7), the 2D CSI produced spectra
of insufficient quality and SVS was instead utilized.
Single-voxel spectroscopy was performed in two pa-
tients, both with brainstem lesions. The following
parameters were used for SVS: PRESS sequence, TE/TR
144/1500 ms, FOV 24 cm, matrix 1·1, scan thickness of
20 mm, scan time 3:48 min. In one patient (no. 1), the
VOI was placed on a non-angled FLAIR image, and in
the other patient (no. 7) the VOI was placed on the
coronal contrast-enhanced T1-weighted images, which
were felt to display the lesion best. In both patients, SVS
was performed with the VOI placed over the lesion, and
a second examination was performed with the VOI
placed in normal appearing occipital white matter.
In addition to the out-of-field-of-view saturation
bands that are routinely placed in all MRS examina-
tions, within-field-of-view saturation bands for sup-
pression of osseous regions adjacent to the tissues of
interest were placed when necessary, as shown in Fig. 1.
Automatic pre-scanning was performed twice before
each spectroscopic scan to assure adequate water sup-
pression and acceptable full-width half-maximum
(FWHM) values.
The data were postprocessed on a workstation (GE
Sun) using Functool 2000. The spectra were analyzed for
the signal intensity of the following metabolites: N-ace-
tyl-aspartate (NAA), choline (Cho), creatine (Cr) and
presence of lactate (Lac). The following ratios were
calculated: NAA/Cr, Cho/Cr, and Cho/NAA. The
identity of a contrast enhancing lesion as either tumor
recurrence or treatment-related changes was determined
based on tissue biopsy in two patients (nos. 6 and 8), and
based on subsequent clinical course and imaging follow-
up examinations in the remaining six patients.
Results
MR spectroscopy performed over the contrast-enhanc-
ing lesion identified on diagnostic MRI in the posterior
fossa revealed metabolic spectra consistent with tumor
recurrence in five of the eight cases, while treatment-
related changes and lack of tumor was confirmed in
three cases.
The imaging features of lesions determined to be
tumor recurrence appeared as solitary contrast-enhanc-
Fig. 1a, b Within-field-of-view
saturation bands placed in
sagittal and coronal projections
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ing nodules in the brainstem or cerebellum. These
imaging characteristics plus their metabolic ratios were
suggestive of tumor recurrence in five patients (patients
1–5) (Figs. 2, 3, 4). This was confirmed by progression of
the lesions on subsequent imaging studies and by pro-
gression of clinical symptoms. In contrast, in the three
cases that showed patchy multiple areas of contrast
enhancement, the metabolic spectra were suggestive of
Fig. 2a–c T1-weighted axial images after contrast administration
demonstrate a new contrast-enhancing lesion in a 61-year-old male
who had undergone radiation therapy for suspected brainstem
glioma (a, arrow). SVS (PRESS, TE 144 ms, TR 1500 ms) was
performed owing to the suitable location of the lesion, with the
VOI over the contrast-enhancing lesion (b). Significant tenfold
elevated signal intensity of the choline and marked decrease of
NAA consistent with recurrent tumor (c). Progression on
subsequent imaging and of clinical symptoms confirmed the
diagnosis of tumor recurrence
Fig. 3a–c Axial T1-weighted images after contrast administration
demonstrate a focal contrast-enhancing lesion in the right
cerebellar peduncle in a 33-year-old woman status post resection,
chemo- and radiation therapy for a brainstem glioma (a). 2D-CSI
(PRESS, TE 144 ms, TR 1000 ms) was performed and additional
within-field-of-view saturation bands were used to decrease
susceptibility artifacts from bone, CSF, and air. The Cho/Cr was
markedly elevated (3.04) and the NAA/Cr decreased (0.47). The
Cho/NAA ratio was 6.47. The findings were consistent with
recurrent neoplasm (b, c)
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treatment-related changes (patients 6–8) (Figs. 5, 6). The
absence of tumor was confirmed by biopsy (patients 6
and 8), and by resolution of abnormal contrast
enhancement over time (patient 7).
Metabolite ratios for each patient are given in
Table 2, and the mean and range of the metabolite ratios
in patients with tumor recurrence, in those with treat-
ment-related change, and in normal-appearing white
matter are summarized in Table 3. The Cho/Cr and
Cho/NAA ratios were higher in the tumor lesions
(means 2.93, and 4.34, respectively) than in the treat-
ment-related changes (means 1.62, and 1.74, respec-
tively) and were lowest in the normal-appearing white
matter (means 0.97, and 0.93, respectively). The values
obtained by SVS in patients 1 and 7 are not included in
these calculations, but displayed separately in Tables 2
and 3. With one exception there was no overlap in the
individual Cho/Cr and Cho/NAA ratios between the
three types of tissue. The NAA/Cr ratio was higher in
the normal-appearing white matter (mean 1.26) than in
the contrast-enhancing areas of tumor (mean 0.74) or
treatment-related changes (mean 0.92). The presence of
a lactate peak was seen in one patient (no.7). While
trends are evident, no statistical analysis was performed
on these eight patients because of the small sample size.
Single-voxel spectroscopy was performed in two of
the eight patients. In the first patient (no. 1) (Fig. 2a–c),
only single-voxel spectroscopy was performed, as this
lesion was relatively large and homogeneous and its
location in the brainstem made it suitable for SVS.
Satisfactory spectra were obtained, but the choline was
so dramatically increased (greater than tenfold above
baseline) that discernible creatine and NAA peaks were
not quantifiable.
In the other patient (no.7) (Fig. 6a–d), despite mul-
tiple attempts, 2D CSI resulted in suboptimal spectra.
SVS was thus performed with voxel placed on coronal
images (Fig. 6b, c), resulting in sufficient quality spectra
with ratios between the values for normal white matter
and those thought to represent recurrence (Table 2),
thus suggesting treatment-related changes.
Discussion
Although the number of patients is small, this study
shows that it is possible to perform 2D CSI with high-
quality spectra in the posterior fossa structures, a
technically challenging region, and in a difficult type
Fig. 4a–c Axial T1-weighted images after contrast administration
demonstrate a new contrast-enhancing lesion in a 41-year-old
woman who had undergone radiation therapy and surgical
resection for a cerebellar astrocytoma 2 years previously (a)
(arrows). 2D-CSI (PRESS, TE 144 ms, TR 1000 ms) was
performed with in-field-of-view saturation bands to diminish
susceptibility artifacts of CSF, bone and air (b), VOI placed on
non-angled axial flair images. The Cho/Cr, NAA/Cr and Cho/
NAA ratios were 1.65, 0.74 and 2.23, respectively, and the findings
were strongly suggestive of recurrent neoplasm (c). The patient
underwent additional chemotherapy for this lesion and has had no
progression in the disease to date
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of lesions in most patients. We have achieved this by
optimizing 2D CSI with proper placement of satura-
tion bands, repeat prescanning and using the
described imaging parameters, as demonstrated previ-
ously [19].
As has been shown in the only similar study exam-
ining normal subjects [15], and as in one of our
patients (no.7), 2D-CSI may not be of diagnostic quality
and information of the metabolic characteristics some-
times must be obtained using SVS. In contrast to the
prior study [15] we used in-field-of-view-saturation
bands in addition to multiple outer volume suppression
slices (OVS) for lipid suppression. These technical
considerations helped to reduce various potential arti-
facts from air, bone, and CSF that are inherently more
disturbing in the infra- than the supratentorial
compartment.
A range of normal metabolite ratios, depending on
the anatomic location within the posterior fossa, has
been reported using 2D-CSI (15) and SVS [20]. The
Cho/Cr ratios for normal white matter in our study
(0.83–1.39) are in excellent agreement with Cho/Cr
ratios in normal white matter (0.85–1.47) reported pre-
viously [15], and for NAA/Cr the ratios (1.13–1.52) are
also within the realm (1.20–2.33) of those reported by
others [15].
A recent analysis of normal volunteers and 43
patients with primary glial tumors has found NAA/Cr
ratios significantly lower in the tumor bed after radiation
therapy and, moreover, the NAA/Cr ratios were
inversely proportional to the dose of radiation received
[21]. Similarly, in our study, all NAA/Cr ratios in areas
of recurrent tumor or treatment-related changes were
lower than those in normal white matter. Another study
in patients with histopathologically proven supratento-
rial gliomas treated with radiation therapy has shown
lower Cho/Cr ratio in those with radiation change than
in those with recurrent tumor [22]. In agreement with
these results, our results also suggest that the choline
content in radiation change lies between that of normal
brain tissue and that of recurrent tumor.
The spread of the metabolite ratios is explained in
part by differences in the anatomic location [15, 20] of
each of these lesions, but also by the inevitable volume
averaging of normal and abnormal tissues within the
same voxel. Single-voxel spectroscopy is particularly
prone to such volume averaging, and indeed our
Fig. 5a–c Axial and coronal T1-weighted images after contrast
administration demonstrate ill-defined patchy areas of new
enhancement involving the vermis and both cerebellar hemispheres
(a, arrows). 2D-CSI (PRESS TE/TR 144/1000 ms) was performed
with the VOI covering both cerebellar hemispheres (b). Spectra
with easily quantifiable choline, creatine, and NAA peaks were
obtained. While Ch/Cr ratios for this lesion (1.61) were slightly
elevated above normal adjacent occipital lobe white matter (0.86),
and NAA/Cr ratios were slightly decreased (0.94), neither of these
changes was as dramatic as expected for tumor recurrence. The
result was interpreted as treatment-related changes (c). Subsequent
biopsy of these cerebellar lesions confirmed the presence of tumor
necrosis and lack of tumor cells
546
two patients who underwent SVS were at the extreme of
the ranges both for the Cho/Cr ratio within the lesion
and the NAA/Cr ratio in normal white matter.
Specifically in the type of lesions analyzed here, the
spread of values is also likely explained by the known
scenario in which a recurrent tumor arises in a bed
Fig. 6a–d Coronal T1 weighted
images after contrast adminis-
tration demonstrate focal pat-
chy contrast enhancement in
the brainstem and cerebellar
hemispheres in a 14-year-old
boy status post resection, che-
mo- and radiation therapy for a
medulloblastoma (a). SVS
spectroscopy (PRESS TE/TR
144/1500 ms) was performed
with the VOI placed on coronal
images (b). Good-quality spec-
tra were obtained and, although
volume averaging of normal
tissue and enhancing lesion
undoubtedly occurred with the
use of single-voxel spectros-
copy, the Cho/Cr, NAA/Cr,
and Cho/NAA ratios for this
lesion were 1.69, 0.90, and 1.88,
respectively. Note was made of
inverted lactate peak (c). MRI
performed 6 months later dem-
onstrated interval improvement
of the abnormalities in the
brainstem and cerebellum (d)
Table 2 The metabolite ratios
of the contrast-enhancing
lesion in each patient (NA
not available)
aThe only overlap among all





1 Recurrence Tenfold increase NA NA
2 Recurrence 3.04 6.47 0.47
3 Recurrence 1.65 2.23 0.74
4 Recurrence 2.79 2.47 1.13
5 Recurrence 4.26 6.19 0.62
6 Treatment-related change 1.61 1.71 0.94
7 Treatment-related change 1.69* 1.88 0.90
8 Treatment-related change 1.64 1.78 0.92
Table 3 The metabolite ratios




aNote that patient 1 with a
more than tenfold increase of
choline is not included in these
calculations






Cho/Cr 2D-CSI 0.97 (0.83–1.39) 1.62 (1.61–1.64) 2.93 (1.65–4.26)
SVS 0.96 1.69
Cho/NAA 2D-CSI 0.93 (0.56–1.23) 1.74 (1.71–1.78) 4.34 (2.23–6.47)
SVS 0.46 1.88
NAA/ Cr 2D-CSI 1.26 (1.13–1.52) 0.92 (0.87–0.94) 0.74 (0.47–1.13)
SVS 2.09 0.90
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of abnormal tissue that is altered by treatment, which
results in an inevitable averaging of the metabolite
differences that may exist between these two entities.
This is supported by findings of authors correlating
MRS patterns in supratentorial CNS neoplasms with
pathologic results of subsequent tissue analysis who
reported that ‘‘spectral patterns are less definitive when
tissues composed of varying degrees of mixed tumor and
necrosis are examined’’ [3]. However, they found that in
the supratentorial neoplasms a Cho/Cr ratio greater
than 1.79 had a sevenfold increased chance of that tissue
being pure tumor [3]. Interestingly, in our study none of
the Cho/Cr ratios in normal white matter or in treat-
ment-related changes, i.e., not in the recurrent tumor,
reached above 1.69.
In conclusion, also in the posterior fossa, MR spec-
troscopy is likely to be useful as an adjunct to conven-
tional imaging characteristics in distinguishing recurrent
tumor from treatment-related changes, irrespectively of
the MRS technique used. In most cases spectra of
diagnostic quality can be obtained using 2D-CSI, with
coverage including both the lesion and its vicinity.
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